Comparison of conventional and advanced radiotherapy techniques for left-sided breast cancer after breast conserving surgery.
Conventional tangential
Field-in-Field
Intensity-modulated radiotherapy
Lumpectomy
Volumetric modulated arc therapy
Whole breast radiotherapy
Journal
Medical dosimetry : official journal of the American Association of Medical Dosimetrists
ISSN: 1873-4022
Titre abrégé: Med Dosim
Pays: United States
ID NLM: 8908862
Informations de publication
Date de publication:
Historique:
received:
08
02
2020
revised:
22
04
2020
accepted:
20
05
2020
pubmed:
11
7
2020
medline:
25
11
2021
entrez:
11
7
2020
Statut:
ppublish
Résumé
Whole breast radiotherapy (WBRT) after breast conserving surgery is the standard treatment to prevent recurrence and metastasis of early stage breast cancer. This study aims to compare seven WBRT techniques including conventional tangential, field-in-field (FIF), hybrid intensity-modulated radiotherapy (IMRT), IMRT, standard volumetric modulated arc therapy (STD-VMAT), noncoplanar VMAT (NC-VMAT), and multiple arc VMAT (MA-VMAT). Fifteen patients who were previously diagnosed with left-sided early stage breast cancer and treated in our clinic were selected for this study. WBRT plans were created for these patients and were evaluated based on target coverage and normal tissue toxicities. All techniques produced clinically acceptable WBRT plans. STD-VMAT delivered the lowest mean dose (1.1 ± 0.3 Gy) and the lowest maximum dose (7.3 ± 4.9 Gy) to contralateral breast, and the second lowest lifetime attributable risk (LAR) (4.1 ± 1.4%) of secondary contralateral breast cancer. MA-VMAT delivered the lowest mean dose to lungs (4.9 ± 0.9 Gy) and heart (5.5 ± 1.2 Gy), exhibited the lowest LAR (1.7 ± 0.3%) of secondary lung cancer, normal tissue complication probability (NTCP) (1.2 ± 0.2%) of pneumonitis, risk of coronary events (RCE) (10.3 ± 2.7%), and LAR (3.9 ± 1.3%) of secondary contralateral breast cancer. NC-VMAT plans provided the most conformal target coverage, the lowest maximum lung dose (46.2 ± 4.1 Gy) and heart dose (41.1 ± 5.4 Gy), and the second lowest LAR (1.8 ± 0.4%) of secondary lung cancer and RCE (10.5 ± 2.8%). MA-VMAT and NC-VMAT could be the preferred techniques for early stage breast cancer patients after breast conserving surgery.
Identifiants
pubmed: 32646715
pii: S0958-3947(20)30098-4
doi: 10.1016/j.meddos.2020.05.004
pmc: PMC7609481
mid: NIHMS1603616
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e9-e16Subventions
Organisme : NCI NIH HHS
ID : K22 CA204464
Pays : United States
Informations de copyright
Copyright © 2020 American Association of Medical Dosimetrists. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of Interest The authors declare no conflicts of interest.
Références
Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):918-24
pubmed: 17889273
Med Phys. 2003 Aug;30(8):2089-115
pubmed: 12945975
J Med Radiat Sci. 2015 Mar;62(1):66-73
pubmed: 26229669
Am J Clin Oncol. 2006 Feb;29(1):66-70
pubmed: 16462506
Radiother Oncol. 2011 Aug;100(2):236-40
pubmed: 21296441
Cancers (Basel). 2019 Feb 22;11(2):
pubmed: 30813346
Med Dosim. 2020 Spring;45(1):34-40
pubmed: 31129035
Med Phys. 2012 Mar;39(3):1386-409
pubmed: 22380372
Phys Med. 2015 Jun;31(4):360-7
pubmed: 25733372
Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):1148-1156
pubmed: 26050608
Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1623-30
pubmed: 2722599
Pract Radiat Oncol. 2018 May - Jun;8(3):145-152
pubmed: 29545124
Radiat Oncol. 2015 Nov 17;10:231
pubmed: 26577189
Biomed Res Int. 2014;2014:741326
pubmed: 25170514
Int J Radiat Oncol Biol Phys. 2011 Jul 1;80(3):771-8
pubmed: 20584586
Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):922-32
pubmed: 15708276
Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):287-95
pubmed: 19775832
Radiat Oncol. 2015 Sep 22;10:200
pubmed: 26391237
J Clin Oncol. 2017 May 20;35(15):1641-1649
pubmed: 28319436
Med Phys. 2014 Aug;41(8):081712
pubmed: 25086522
Int J Radiat Oncol Biol Phys. 2003 Feb 1;55(2):392-406
pubmed: 12527053
Oncotarget. 2016 Apr 19;7(16):22960-9
pubmed: 27027239
Radiother Oncol. 2013 Dec;109(3):475-81
pubmed: 24231240
Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):724-35
pubmed: 12573760
Radiother Oncol. 1994 Nov;33(2):106-12
pubmed: 7708953
Radiat Res Suppl. 1985;8:S13-9
pubmed: 3867079
Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):197-203
pubmed: 8083114
Med Dosim. 2019 Winter;44(4):e13-e18
pubmed: 30529304
Theor Biol Med Model. 2011 Jul 26;8:27
pubmed: 21791103
J Appl Clin Med Phys. 2012 Sep 06;13(5):3806
pubmed: 22955645
Int J Radiat Oncol Biol Phys. 2018 May 1;101(1):144-151
pubmed: 29619962
J Appl Clin Med Phys. 2013 Jan 07;14(1):4035
pubmed: 23318391
Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):e115-22
pubmed: 22543199
Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):187-94
pubmed: 10656392
Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):1023-8
pubmed: 11240243
Oncol Rep. 2014 May;31(5):2195-205
pubmed: 24604635
J Med Radiat Sci. 2015 Mar;62(1):74-81
pubmed: 26229670
Acta Oncol. 2011 Jan;50(1):42-50
pubmed: 20843181
J Appl Clin Med Phys. 2016 Nov 08;17(6):60-68
pubmed: 27929481
Radiother Oncol. 2005 Sep;76(3):319-25
pubmed: 15921771
J Appl Clin Med Phys. 2018 May;19(3):79-86
pubmed: 29524290
Int J Radiat Oncol Biol Phys. 1997 Feb 1;37(3):731-6
pubmed: 9112473
Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):573-85
pubmed: 12738335
Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):73-81
pubmed: 17337131
J Exp Clin Cancer Res. 2013 Nov 07;32:88
pubmed: 24423396
Br J Radiol. 2019 May;92(1097):20180908
pubmed: 30694086
Radiat Oncol. 2013 Apr 15;8:89
pubmed: 23587298
Comput Biol Med. 2014 Oct;53:134-40
pubmed: 25147130
JAMA. 2007 Feb 14;297(6):611-9
pubmed: 17299196
Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):91-9
pubmed: 19395189
J Natl Cancer Inst. 2007 Mar 7;99(5):365-75
pubmed: 17341728
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S70-6
pubmed: 20171521
Radiat Oncol. 2015 Apr 08;10:79
pubmed: 25888866
Radiother Oncol. 2014 Jul;112(1):17-22
pubmed: 24825176
N Engl J Med. 2013 Mar 14;368(11):987-98
pubmed: 23484825
Radiother Oncol. 2011 Aug;100(2):241-6
pubmed: 21316783
J Appl Clin Med Phys. 2015 May 08;16(3):5266
pubmed: 26103488